DM
Deerfield Management Portfolio holdings
AUM
$5.51B
This Quarter Return
-5.4%
1 Year Return
+12.76%
3 Year Return
+152.98%
5 Year Return
+204.91%
10 Year Return
+993.1%
AUM
$5.04B
AUM Growth
+$5.04B
(-4%)
Cap. Flow
+$166M
Cap. Flow
% of AUM
3.28%
Top 10 Holdings %
Top 10 Hldgs %
52.76%
Holding
153
New
45
Increased
20
Reduced
17
Closed
29
Top Buys
| 1 |
United Therapeutics
UTHR
|
$84.8M |
| 2 |
Pfizer
PFE
|
$84.8M |
| 3 |
Neurocrine Biosciences
NBIX
|
$69.3M |
| 4 |
Insmed
INSM
|
$34.9M |
| 5 |
Vera Therapeutics
VERA
|
$25.2M |
Top Sells
| 1 |
WAY
Waystar Holding Corp
WAY
|
$121M |
| 2 |
Owens & Minor
OMI
|
$64.2M |
| 3 |
Alignment Healthcare
ALHC
|
$51M |
| 4 |
Galapagos
GLPG
|
$38.8M |
| 5 |
BCAX
Bicara Therapeutics Inc. Common Stock
BCAX
|
$31.3M |
Sector Composition
| 1 | Healthcare | 87.58% |
| 2 | Real Estate | 0.01% |
| 3 | Technology | 0.01% |
| 4 | Consumer Discretionary | 0.01% |
| 5 | Energy | 0.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
BioCryst Pharmaceuticals
BCRX
$1.74B
| $38.9M | 0.77% |
5,189,665
-2,954,777
| -36% | -$22.2M |
|
27
Disc Medicine
IRON
$2.14B
| $38.8M | 0.77% |
782,333
+181,818
| +30% | +$9.03M |
|
28
CONMED
CNMD
$1.64B
| $36.9M | 0.73% |
611,000
-964
| -0.2% | -$58.2K |
|
29
Envista
NVST
$3.37B
| $35M | 0.69% |
2,024,943
+1,006,528
| +99% | +$17.4M |
|
|
30
Insmed
INSM
$30.3B
| $34.9M | 0.69% |
+458,000
| New | +$34.9M |
|
31
Embecta
EMBC
$837M
| $34.7M | 0.68% |
2,720,535
-550,000
| -17% | -$7.01M |
|
|
CMRX
32
DELISTED
Chimerix, Inc.
CMRX
| $32.1M | 0.63% |
3,771,342
| – | – |
|
33
Pharvaris
PHVS
$1.41B
| $31.7M | 0.63% |
2,017,464
| – | – |
|
34
Cullinan Oncology
CGEM
$456M
| $29.2M | 0.58% |
3,860,839
+481,440
| +14% | +$3.64M |
|
35
InMode
INMD
$917M
| $28M | 0.55% |
1,578,708
| – | – |
|
36
Phreesia
PHR
$1.81B
| $25.8M | 0.51% |
1,009,844
-261,988
| -21% | -$6.7M |
|
|
37
Vera Therapeutics
VERA
$1.47B
| $25.2M | 0.5% |
+1,050,000
| New | +$25.2M |
|
38
Liquidia Corp
LQDA
$2.52B
| $23.8M | 0.47% |
+1,616,778
| New | +$23.8M |
|
39
Day One Biopharmaceuticals
DAWN
$766M
| $23.5M | 0.46% |
2,960,740
+364,707
| +14% | +$2.89M |
|
40
Praxis Precision Medicines
PRAX
$980M
| $23.5M | 0.46% |
+619,931
| New | +$23.5M |
|
41
Lantheus
LNTH
$3.75B
| $23.4M | 0.46% |
240,218
| – | – |
|
42
Savara
SVRA
$591M
| $22.1M | 0.44% |
7,964,000
| – | – |
|
43
CG Oncology
CGON
$2.19B
| $20.8M | 0.41% |
850,695
-898
| -0.1% | -$22K |
|
44
Certara
CERT
$1.69B
| $20M | 0.4% |
+2,022,616
| New | +$20M |
|
45
Integra LifeSciences
IART
$1.18B
| $17.5M | 0.35% |
+794,865
| New | +$17.5M |
|
46
Beam Therapeutics
BEAM
$1.9B
| $17.1M | 0.34% |
+877,809
| New | +$17.1M |
|
47
Kymera Therapeutics
KYMR
$3.1B
| $16.2M | 0.32% |
593,000
| – | – |
|
48
Cogent Biosciences
COGT
$1.83B
| $15.8M | 0.31% |
2,633,862
+2,862
| +0.1% | +$17.1K |
|
|
MREO
49
Mereo BioPharma
MREO
$275M
| $15.1M | 0.3% |
6,710,429
| – | – |
|
|
CON
50
Concentra Group Holdings Parent, Inc.
CON
$3.04B
| $14.1M | 0.28% |
650,000
| – | – |
|